Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study
Authors
- Zhefeng Liu (ORCID: https://orcid.org/0000-0002-6160-7194)
- Yi Hu (ORCID: https://orcid.org/0000-0001-9319-5692)
- Haitao Tao (ORCID: https://orcid.org/0009-0001-1295-8692)
- Guoqing Zhang (ORCID: https://orcid.org/0000-0002-8881-9453)
- Jinliang Wang (ORCID: https://orcid.org/0000-0001-7202-646X)
- Lijie Wang (ORCID: https://orcid.org/0000-0001-8674-3128)
- Yining Liu (ORCID: https://orcid.org/0000-0001-8418-1360)
- Junxun Ma
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.cpt.2025.08.005
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00